Comparing Characteristics of Pelvic High-grade Serous Carcinomas with and without Breast Cancer Gene Variants on MR Imaging

被引:0
作者
Saida, Tsukasa [1 ]
Shikama, Ayumi [2 ]
Mori, Kensaku [1 ]
Ishiguro, Toshitaka [1 ]
Minaguchi, Takeo [2 ]
Satoh, Toyomi [2 ]
Nakajima, Takahito [1 ]
机构
[1] Univ Tsukuba, Dept Radiol, Fac Med, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058575, Japan
[2] Univ Tsukuba, Dept Obstet & Gynecol, Fac Med, Tsukuba, Ibaraki, Japan
关键词
breast cancer; cancer; high-grade serous carcinoma; magnetic resonance imaging; ovary; SOMATIC MUTATIONS; INVASION PATTERNS; FALLOPIAN-TUBE; OVARIAN; BENEFIT; BRCA1; GERMLINE; SURVIVAL; PLATINUM;
D O I
暂无
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose: To compare MRI findings of high-grade serous carcinoma (HGSC) with and without breast cancer (BRCA) gene variants to explore the feasibility of MRI as a genetic predictor. Methods: We retrospectively reviewed MRI data from 16 patients with BRCA variant-positive (11 patients of BRCA1 and 5 patients of BRCA2 variant-positive) and 32 patients with BRCA variant-negative HGSCs and evaluated tumor size, appearance, nature of solid components, apparent diffusion coefficient (ADC) value, time-intensity curve, several dynamic contrast-enhanced curve descriptors, and nature of peritoneal metastasis. Age, primary site, tumor stage, bilaterality, presence of lymph node metastasis, presence of peritoneal metastasis, and tumor markers were also compared between the groups with the Mann-Whitney U and chi-square tests. Results: The mean tumor size of BRCA variant-positive HGSCs was 9.6 cm, and that of variant-negative HGSCs was 6.8 cm, with no significant difference (P = 0.241). No significant difference was found between BRCA variant-positive and negative HGSCs in other evaluated factors, except for age (mean age, 53 years old; range, 32-78 years old for BRCA variant-positive and mean age, 61 years old; range, 44-80 years old for BRCA variant-negative, P = 0.033). Comparing BRCA1 variant-positive and BRCA2 variant-positive HGSCs, BRCA1 variant-positive HGSCs were larger (P = 0.040), had greater Max enhancement (P = 0.013), Area under the curve (P = 0.013), and CA125 (P = 0.038), and had a higher frequency of lymph node metastasis (P = 0.049), with significance. Conclusion: There was no significant difference in the MRI findings between patients with HGSCs with and without BRCA variants. Although studied in small numbers, BRCA1 variant-positive HGSCs were larger and more enhanced than BRCA2 variant-positive HGSCs with higher CA125 and more frequent lymph node metastases, and may represent more aggressive features.
引用
收藏
页码:18 / 26
页数:9
相关论文
共 50 条
  • [41] Integrated weighted gene co-expression network analysis reveals biomarkers associated with prognosis of high-grade serous ovarian cancer
    Wang, Bo
    Chao, Shan
    Guo, Bo
    JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2022, 36 (02)
  • [42] The NER-related gene GTF2H5 predicts survival in high-grade serous ovarian cancer patients
    Gayarre, Javier
    Kamieniak, Marta M.
    Cazorla-Jimenez, Alicia
    Munoz-Repeto, Ivan
    Borrego, Salud
    Garcia-Donas, Jesus
    Hernando, Susana
    Robles-Diaz, Luis
    Garcia-Bueno, Jose M.
    Ramon y Cajal, Teresa
    Hernandez-Agudo, Elena
    Heredia Soto, Victoria
    Marquez-Rodas, Ivan
    Jose Echarri, Maria
    Lacambra-Calvet, Carmen
    Saez, Raquel
    Cusido, Maite
    Redondo, Andres
    Paz-Ares, Luis
    Hardisson, David
    Mendiola, Marta
    Palacios, Jose
    Benitez, Javier
    Jose Garcia, Maria
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2016, 27 (01)
  • [43] Constitutional BRCA1 and MGMT Methylation Are Significant Risk Factors for Triple-Negative Breast Cancer and High-Grade Serous Ovarian Cancer in Saudi Women
    Al-Moghrabi, Nisreen
    Al-Showimi, Maram
    Alqahtani, Amal
    Almalik, Osama
    Alhusaini, Hamed
    Almalki, Ghdah
    Saad, Ajawhara
    Alsunayi, Elaf
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (06)
  • [44] Population-based targeted sequencing of 54 candidate genes identifies PALB2 as a susceptibility gene for high-grade serous ovarian cancer
    Song, Honglin
    Dicks, Ed M.
    Tyrer, Jonathan
    Intermaggio, Maria
    Chenevix-Trench, Georgia
    Bowtell, David D.
    Traficante, Nadia
    Brenton, James
    Goranova, Teodora
    Hosking, Karen
    Piskorz, Anna
    van Oudenhove, Elke
    Doherty, Jen
    Harris, Holly R.
    Rossing, Mary Anne
    Duerst, Matthias
    Dork, Thilo
    Bogdanova, Natalia, V
    Modugno, Francesmary
    Moysich, Kirsten
    Odunsi, Kunle
    Ness, Roberta
    Karlan, Beth Y.
    Lester, Jenny
    Jensen, Allan
    Kruger Kjaer, Susanne
    Hogdall, Estrid
    Campbell, Ian G.
    Lazaro, Conxi
    Pujara, Miguel Angel
    Cunningham, Julie
    Vierkant, Robert
    Winham, Stacey J.
    Hildebrandt, Michelle
    Huff, Chad
    Li, Donghui
    Wu, Xifeng
    Yu, Yao
    Permuth, Jennifer B.
    Levine, Douglas A.
    Schildkraut, Joellen M.
    Riggan, Marjorie J.
    Berchuck, Andrew
    Webb, Penelope M.
    Cybulski, Cezary
    Gronwald, Jacek
    Jakubowska, Anna
    Lubinski, Jan
    Alsop, Jennifer
    Harrington, Patricia
    JOURNAL OF MEDICAL GENETICS, 2021, 58 (05) : 305 - 313
  • [45] Integrated analysis of spatial transcriptomics and CT phenotypes for unveiling the novel molecular characteristics of recurrent and non-recurrent high-grade serous ovarian cancer
    Ju, Hye-Yeon
    Youn, Seo Yeon
    Kang, Jun
    Whang, Min Yeop
    Choi, Youn Jin
    Han, Mi-Ryung
    BIOMARKER RESEARCH, 2024, 12 (01)
  • [46] P53 PROTEIN EXPRESSION IN FINE-NEEDLE ASPIRATES OF BREAST-CANCER - AN IMMUNOCYTOCHEMICAL ASSAY FOR IDENTIFYING HIGH-GRADE DUCTAL CARCINOMAS
    COLECCHIA, M
    FRIGO, B
    ZUCCHI, A
    LEOPARDI, O
    DIAGNOSTIC CYTOPATHOLOGY, 1995, 13 (02) : 128 - 132
  • [47] A modified diffusion-weighted magnetic resonance imaging-based model from the radiologist's perspective: improved performance in determining the surgical resectability of advanced high-grade serous ovarian cancer
    Lu, Jing
    Guo, Qinhao
    Zhang, Ya
    Zhao, Shuhui
    Li, Ruimin
    Fu, Yi
    Feng, Zheng
    Wu, Yong
    Li, Rong
    Li, Xiaojie
    Qiang, Jinwei
    Wu, Xiaohua
    Gu, Yajia
    Li, Haiming
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2024, 231 (01) : 117e1 - 117e17
  • [48] BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients - A study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD)
    Ruscito, I.
    Dimitrova, D.
    Vasconcelos, I.
    Gellhaus, K.
    Schwachula, T.
    Bellati, F.
    Zeillinger, R.
    Benedetti-Panici, P.
    Vergote, I.
    Mahner, S.
    Cacsire-Tong, D.
    Concin, N.
    Darb-Esfahani, S.
    Lambrechts, S.
    Sehouli, J.
    Olek, S.
    Braicu, E. I.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 (12) : 2090 - 2098
  • [49] Comparing breast cancer imaging characteristics of CHEK2 with BRCA1 and BRCA2 gene mutation carriers
    Ghunaim, Hadeel
    Laenen, Annouschka
    De Keyzer, Frederik
    Soens, Julie
    Keupers, Machteld
    Postema, Sandra
    Neven, Patrick
    Van Ongeval, Chantal
    EUROPEAN JOURNAL OF RADIOLOGY, 2022, 146
  • [50] Tumour immune cell infiltration and survival after platinum-based chemotherapy in high-grade serous ovarian cancer subtypes: A gene expression-based computational study
    Liu, Rong
    Hu, Rong
    Zeng, Ying
    Zhang, Wei
    Zhou, Hong-Hao
    EBIOMEDICINE, 2020, 51